BioCentury
ARTICLE | Financial News

Neurocrine climbs on Ingrezza approval

April 12, 2017 10:37 PM UTC

Neurocrine Biosciences Inc. (NASDAQ:NBIX) rose $10.32 (25%) to $51.80 on Wednesday, adding about $900 million in market cap, after FDA approved its Ingrezza valbenazine to treat tardive dyskinesia. The approval, the first in the indication, came after market hours Tuesday. Ingrezza is a selective inhibitor of vesicular monoamine transporter 2 (VMAT2; SLC18A2) (see BioCentury Extra, April 11)...